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Abstract
In Croatian medical laboratories (ML), external quality assessment (EQA) has a long tradition of almost half of a century. At national level, EQA is 
provided by Croatian Centre for Quality Assessment in Laboratory Medicine (CROQALM) which is a part of Croatian Society of Medical Biochemistry 
and Laboratory Medicine. 
This case study aimed to summarize the main challenges, which are set to CROQALM and their possible solutions.
CROQALM has 10 schemes, covering majority of analysis for which medical biochemistry laboratories in Croatia are authorized for, including pre-
analytical and post-analytical phase of laboratory work. Assessment scheme has three exercises per year. One sample per scheme and exercise is 
distributed to participants depending on their application. All data transfer and evaluation of the results are done using web interface and statistical 
software for evaluation of quality in laboratory medicine. 
Since CROQALM has relatively small number of participating laboratories (N = 197) with lot of different manufacturers of instruments used for 
analysis in all schemes, constant challenges are present in the evaluation of the results (commutability problems, statistical analysis etc.). Further, 
number of participating medical laboratories is even lower for highly specific parameters, which are in the scope of clinical laboratories only. 
Despite the obstacles we are faced to, EQA at national level is useful tool regarding standardization and harmonization aspects in total testing proce-
ss within the country. Furthermore, it gives participating laboratories recognition and proof for meeting expected quality criteria in the community 
they serve. 
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Introduction
External quality assessment (EQA) is a widely ac-
cepted tool for monitoring and improving method 
performance in the medical laboratory (ML).
Croatian Centre for Quality Assessment in Labora-
tory Medicine (CROQALM) is a part of the Croatian 
Society of Medical Biochemistry and Laboratory 
Medicine (CSMBLM) and serves as a quality evalua-
tion scheme in laboratory medicine at national 
level. Participation in CROQALM is mandatory for 
every ML in Croatia. 
The schemes contained in CROQALM are designed 
to cover majority of analysis preformed in Croatian 
laboratories and are presented in Table 1. The con-
trol samples are distributed one to three times per 
year, depending on the participants’ application 
and the scheme schedule. In each scheduled exer-
cise, one control sample per scheme (with instruc-
tion for sample preparation and measurement 
conditions) is sent to every laboratory requiring 
single measurement of analyte. Variable concen-
Special issue:  External Quality Assessment in Laboratory Medicine
Review
http://doi.org/10.11613/BM.2017.011 Biochemia Medica 2017;27(1):86–92 
  87
Lenicek Krleza J. et al. Challenges and specifics of EQA in Croatia 
tration levels are distributed that cover both nor-
mal and pathological ranges where available. At 
the end of each exercise, statistical evaluation of 
test results is done using inlab2*QALM software 
for quality evaluation in laboratory medicine (IN2 
Group Ltd., Zagreb, Croatia), for each peer group 
consisting of seven or more participants. After out-
lier removal using Tukey model (1), mean, standard 
deviation and coefficient of variation is calculated 
for each peer group. The data are further evaluat-
ed according to predefined allowable limits of per-
formance and z-scores with graphical presentation 
and main histogram for every analyte (Figure 1). 
Each laboratory receives report showing calculat-
ed percentage deviation of the result from corre-
sponding peer group mean and z-score in abso-
lute number showing positioning of the individual 
result regarding target value and standard devia-
tion after outlier exclusion. Also, scheme coordina-
tor comments performance characteristics for a 
given EQA exercise as a part of summary report. 
The annual report includes the Certificate of par-
ticipation with an indication of the scheme in 
which they participated. The role of CROQALM is 
to implement and provide an assessment tool for 
laboratory performance, while the corrective ac-
tions upon ‘flagged’ results are responsibility of 
each individual laboratory. Evaluation of laborato-
ry performance in Croatia is within the compe-
tence of CCMB and its professional supervision.
Number of participants varies slightly from one ex-
ercise to the other depending on participants’ ap-
plication and scheme distribution schedule. The 
most of the ML in the CROQALM scheme are part 
of primary health care and thus most results are 
received for routine haematology and biochemis-
try analytes. In 2015, number of registered ML that 
participated in CROQALM was 197. Number of par-








I Biochemistry parameters 3 Human-based, lyophilised control sample 180
II Specific proteins, CRP 3 Human-based lyophilised or liquid control sample 168
III Laboratory haematology 3 Stabilized donor blood and human-based whole blood sample 183
IV Laboratory coagulation, Coagulation factors
3
1 Lyophilised control sample 164
V Drugs 1 Lyophilised control sample 17
VI Urinalysis: urine test strip, sediment 31 Human-based, liquid control sample 178
VII Analysis of pH, blood gases and electrolytes 3 Liquid control sample 41
VIIA Point-of-care: pH, blood gases, electrolytes, glucose and lactate 3 Liquid control sample 19
VIII Hormones, vitamins, tumor and cardiac markers 2 Human-based, lyophilised control sample 94
IX Glycosylated haemoglobin A1c(HbA1c) 3 Human-based lyophilised control sample 151
X Pre-analytical phase of laboratory testing 3 Questionnaire design 168
XI Post-analytical phase of laboratory testing 3 Questionnaire design 160
XII Sweat chloride test 3 In-house liquid control sample 8
Table 1. External quality assessment scheme in Croatia (CROQALM): an overview
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Figure 1. Example of statistical evaluation of results for alanine-aminotransferase.
Graphs: histogram of all results (main graph), positioning of results in allowable grey areas according to z-score (top right) and allow-
able limits of performance (down right).
Statistical evaluation: all method group (number of participants, mean, SD, CV) – first line, method-based peer groups (number of 
participants, mean, SD, CV and laboratory’s result). 
Following lines: overview of deviations according to z-score and according to allowable limits of performance.
CV – coefficient of variation. SD – standard deviation.
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ticipants is different between schemes, from 8 in 
sweat chloride test scheme to 183 in laboratory 
haematology scheme. 
CROQALM scheme is an operational tool for medi-
cal laboratories in evaluating assay performance 
and thus improving analytical phase of laboratory 
work. It also encourages all attempts in setting 
quality standards for extra analytical phase be-
cause pre- and post-analytical phase of the labora-
tory testing process are major sources of errors for 
total laboratory process. For this reason, in 2014, 
two additional schemes were introduced: pre-ana-
lytical and post-analytical phase schemes which 
are not mandatory and serve only for educational 
purposes. Pre-analytical phase scheme for CRO-
QALM is implemented in cooperation with the 
Working Group for pre-analytics of CSMBLM using 
the circulating questionnaire, one of three method 
types suggested by Kristensen et al. (2), same as 
post-analytical phase scheme where questions are 
categorized into four groups according to quality 
indicators from ‘Model of quality indicators’ pro-
posed by International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC) and 
Working Group ‘Laboratory Errors and Patient 
Safety’ (3). Results and final reports are presented 
like absolute numbers and percentages for each 
answer of questionnaire with coordinators’ com-
ments for these two schemes. 
Depending on sample characteristics, target value 
assignment by reference method and replicate 
samples in each survey, EQA schemes can be clas-
sified into six categories. Category 1 EQA scheme 
is the most challenging one, requiring distribution 
of commutable, replicate samples with values as-
signed by reference method. Consequently, it of-
fers evaluation of bias and reproducibility for an 
individual laboratory and verification of degree of 
standardisation and harmonisation of the meas-
urements procedures used (4). Although Croatian 
EQA scheme aims towards category 1 scheme 
where possible, from which participants would 
get the most information and benefit, several is-
sues have to be resolved. They include commuta-
bility of distributed control samples, accuracy 
evaluation through target value assignment by 
reference method, peer group formation and har-
monisation of laboratory results on national level. 
The aim of this case report is summary of CRO-
QALM main challenges and activities undertaken 
in solving main problems. 
Sample characteristics: commutability 
and target values
Reaching commutable samples that would be-
have in the same manner as patient sample across 
a variety of methods and instruments used in the 
scheme is a major prerequisite for both standardi-
sation and harmonisation (4,5). The issue was of 
utmost importance in haematology scheme 
where different analysers use technologies that 
yield different results for white blood cell count 
(WBC) and/or their subpopulations and the results 
are often flagged. After exploring several different 
commercial samples designed as haematology 
control samples, it was decided that use of mini-
mally preserved fresh blood samples from blood 
donors would give the best baseline sample char-
acteristics and mimic actual patient samples. Ali-
quots of such fresh sample from blood donor were 
distributed in two exercises in 2015 and gave us 
the opportunity to evaluate both laboratories’ 
performances and harmonisation issues. Possible 
shortcoming for this kind of sample is analytical 
range that is restricted to values mostly falling 
within the reference interval.
Although standardisation process is an on-going 
process that involves both manufacturers and lab-
oratories, the role of an EQA scheme should be to 
verify the correct implementation of traceability 
where reference system is available (5,6). In order 
to monitor and support all initiatives to harmonize 
measurement procedure results, distribution of 
commutable samples in the EQA scheme is re-
quired. Commutable control material shows the 
same mathematical relationship between the re-
sults of different measurement procedures as ac-
tual patient sample that contained the same ana-
lyte concentration. It enables assessing both 
method and individual laboratory performance 
evaluation to reference measurement procedure. 
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General biochemistry scheme offers such possibil-
ities since target values determined by reference 
method are available for many analytes enabling 
verification of accuracy. Nevertheless, laboratory 
evaluation is still restricted to peer group consen-
sus value given that the commutability of such 
material has not been verified yet. Obvious limita-
tion of such approach is recognised and was set as 
primary challenge to overcome. 
The preliminary studies have been started by CRO-
QALM to verify commutability of commercial con-
trol material comparing the results of currently 
used control sample with results obtained from 
patient serum. The serum is prepared as ‘off the 
clot’ pooled serum from two donors and fresh ali-
quots were shipped to participants. All samples 
were distributed within two days of shipment and 
participants were instructed to analyse the sam-
ples (both control sample and serum sample) on 
the same run on the instrument. The analytes and 
instruments used were all part of general bio-
chemistry scheme. Such sample may be consid-
ered as native spy-sample used with other EQA 
providers to monitor commutability of distributed 
control material (7). Analysing the results of pre-
liminary studies offers the possibility to address 
both commutability and harmonisation issues in 
the scheme. 
Target value assessing by reference method is an-
other, rather expensive challenge for the small 
scheme. Obtaining such values from accredited 
reference laboratory listed in Joint Committee for 
Traceability in Laboratory Medicine database (8) 
can be achieved by sending substantial amount of 
control material to the reference laboratory after 
assessing its commutability. More practical solu-
tion may be collaboration with other EQA provid-
ers and reference laboratories in reducing costs by 
sharing samples with target values determined in 
reference laboratories (6).
Peer group formation
Peer group consensus value is the basis for labora-
tories evaluation throughout whole Croatian EQA 
scheme. Peer group usually consists of laborato-
ries performing the analysis on same instrument, 
since it can be expected that each instrument will 
have the same matrix-related bias for a given sam-
ple. Besides these matrix-related differences, in-
strument-based peer groups seem like the only 
appropriate evaluation of numerous analytes (hor-
mones, tumour and cardiac markers) in immuno-
assay schemes where lack of standardisation and/
or harmonisation yields different results among 
participating laboratories that use similar princi-
ples, yet slightly different methodologies.
Instrument-based peer groups were not the main 
choice in general biochemistry scheme although 
it would seem like a reasonable choice when com-
mutability hasn’t been verified. One of the reasons 
was an attempt to obtain satisfactory statistical 
evaluation over many instruments used, with 
many homogeneous instrument groups having 
less than 10 participants. Besides statistical rea-
sons, many laboratories (up to 20%) use heteroge-
neous (“open”) systems regarding instrument and 
reagent manufacturer as well as calibrators, which 
makes it difficult to decide on appropriate peer 
(instrument, reagent or calibrator). Nevertheless, 
the groups were further split to instrument-based 
subgroups when substantial difference among in-
struments used was observed (i.e. alkaline phos-
phatase – IFCC method group, cholinesterase – 
butyryltiocholine method group). This approach 
needs constant monitoring and evaluation for up-
coming changes regarding group homogeneity. 
Method-based peer group evaluation is also the 
current choice for urinalysis (urine test strips and 
sediment) scheme. The reasons are numerous 
combinations and different urine test strips and in-
struments used (resulting in large number of small 
and heterogeneous peer groups), as well as many 
laboratories still using visual evaluation of colour-
changes observed. The results received for a given 
control sample are evaluated by CROQALM team 
using several criteria: package insert assigned val-
ues (available from control sample manufacturer), 
percentage of laboratories reporting the same re-
sult and medical decision criteria to which this re-
sult can be applied. All of the above criteria are ob-
jects for professional opinion from EQA scheme 
coordinators which results in a consensus accept-
able performance range for every parameter.
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Allowable limits of performance
Although different models in defining analytical 
quality specification criteria and the hierarchy of 
these principles are defined (9), the acceptable 
limits vary widely among different EQA schemes. 
Because of the limited data for  specifications 
based on clinical outcome (10), limits based on 
components of biological variation and current 
‘state-of-the-art’ in analytical measurements 
(models 2 and 3) are currently applied in CRO-
QALM scheme. Allowable limits of performance 
for the analytes that represent most commonly re-
quested tests in laboratories are documented and 
well known to participants (11), but the rationale of 
their choice must be revised and clear to partici-
pants. Since individual result is evaluated as the 
difference from the target value, both bias and im-
precision is assessed in one total error of measure-
ment. However, expert opinion regarding the ba-
sis for choice between desirable, optimal or mini-
mum specifications derived from intra- and inter-
individual biological variation must be explained 
for participants. For example, the analyte that is 
used in both monitoring and diagnostic purpose 
might require limits that are approaching optimal 
specifications (as it is the case for glucose, where 
allowable percentage deviation from target value 
is set to ± 5%), taking into consideration current 
performances within the EQA scheme, statistical 
limitations (number of participants in the corre-
sponding peer group), current state-of-the-art etc. 
On the other hand, if technical or analytical limita-
tions do not allow specifications based on biologi-
cal variation data to be applied (as for sodium or 
chloride in general biochemistry scheme) or statis-
tical reasons (small or heterogeneous peer groups) 
are the reasons to adopt less stringent,  state-of-
the-art criteria (fibrinogen, antithrombin in coagu-
lation scheme) such particularities must also be 
explained.  It is also mandatory that criteria cur-
rently used is revised (especially for the state-of-
the-art criteria) and time period for monitoring 
any upcoming changes in performance character-
istics defined.
Currently, all allowable limits of performance are 
under revision from scheme’s coordinators and 
their working groups. The hierarchy of acceptable 
limits, as described in Sandberg et al. (9), must be 
followed and basis for every limit must be docu-
mented and shared with participants. When 
choosing analytical specifications deriving from 
biological variation data, one must take into con-
sideration the clinical ‘purpose’ of the analyte 
(monitoring, diagnosis, clinical classification of pa-
tient, point-of-care analysis) and current perfor-
mance in EQA scheme in order to set more strin-
gent, yet achievable and encouraging allowable 
limits of performance. Revised limits must be de-
scribed and the time-period for their re-evaluation 
defined. Also, dual set of criteria in statistical evalu-
ation of data depending on the concentration of 
the analyte is under consideration. It is our opinion 
that having fixed, absolute allowable deviations 
from target value at low concentrations and pro-
portional deviation limit at higher values would be 
more appropriate when dealing with small num-
bers and still ‘fit-for-purpose’. Regardless of ration-
ale used in defining analytical specifications, the 
basis for their choice must be explained and avail-
able to participants (12,13).
Conclusion
Considering total number of laboratories partici-
pating in CROQALM, the scope of analysis and va-
riety of analytical systems within every scheme, it 
might be thought that the laboratories would 
benefit more by participating in an internationally 
organised EQA scheme. Regardless of these obsta-
cles, nationally organised EQA schemes are impor-
tant for laboratory comparison in addressing 
standardisation and harmonisation of total labora-
tory process and give participating laboratories 
recognition and a proof of meeting expected per-
formance criteria within clinical community they 
serve.
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